Button Capital

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

Nanjing Quest Genomics Co., Ltd. specializes in the research, development, and production of instruments and reagents for tumor gene detection, with a particular emphasis on tumor liquid biopsy. Founded in 2012 and headquartered in Nanjing, China, the company is dedicated to advancing genetic testing technologies, particularly in the areas of digital PCR and next-generation sequencing (NGS). Quest Genomics has developed a range of products for detecting mutations in key genes, including HER2, PIK3CA, EGFR, and KRAS, aimed at facilitating targeted therapy and monitoring minimal residual disease (MRD) in cancer patients. Their solutions support the early diagnosis of tumor recurrence, metastasis, and disease progression, thereby enhancing treatment outcomes. Additionally, the company maintains a technology development and overseas market center in San Diego, California, to bolster its global reach and innovation capabilities.

Epintek specializes in the biomedical and medical device sectors, offering a range of services that include preclinical research, inspection, and testing. The company serves as a contract research organization (CRO) for medical institutions and manufacturers of medical equipment. By providing reliable preclinical inspection services, Epintek supports clients in navigating the complexities of regulatory requirements, including registration and clinical trials.

Sinorda Biomedicine Ltd. is a Chinese company dedicated to the development of innovative therapies in the field of biomedicine, particularly focusing on small molecules and T cell cancer immunotherapeutics. The company specializes in various tumor immunotherapy approaches, including anti-tumor sentinel lymph node T-cell therapy, oncolytic virus therapy, and several forms of T-cell and natural killer cell therapies. Additionally, Sinorda Biomedicine offers services such as immune cell isolation, cryopreservation, accurate genetic testing, and immune function assessments. Their research and development initiatives are complemented by production capabilities aimed at advancing clinical trials and the industrialization of their therapeutic solutions.

iBanker is an education management startup based in Beijing that focuses on online financial education. The company aims to be the leading learning platform for financial and quasi-financial professionals in China. Its platform offers a variety of financial practice courses, including investment banking, industry research, asset management, and financial analysis. By providing diverse and multi-tiered educational resources, iBanker addresses the learning needs of users across different sectors within the financial industry.

LAKEbio to provide a series of liquid biopsies preservation products based on gene detection and other new technologies.